Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy

Overview

Journal Nutrients

Date 2020 Oct 29

PMID 33114210

Citations 24

Authors

Triantafyllos Didangelos

Eleni Karlafti

Evangelia Kotzakioulafi

Zisis Kontoninas

Charalampos Margaritidis

Parthena Giannoulaki

Konstantinos Kantartzis

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the efficacy of Superoxide Dismutase, Alpha Lipoic Acid, Acetyl L-Carnitine, and Vitamin B12 (B12) in one tablet in Diabetic Neuropathy (DN).

Patients-methods: In this prospective, double-blind, placebo-controlled study, 85 patients with Diabetes Mellitus Type 2 (DMT2) were randomly assigned, either to receive the combination of four elements (active group, = 43), or placebo ( = 42) for 12 months. We used the Michigan Neuropathy Screening Instrument Questionnaire and Examination (MNSIQ and MNSIE), measured the vibration perception threshold (BIO), and Cardiovascular Autonomic Reflex Tests (CARTs). Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Pain (PS) and quality of life (QL) questionnaires were administered.

Results: At follow-up, BIO, MNSIQ, QL, PAIN, and SNCV, SNAP, and B12 levels had significantly improved inactive group ( <0.001, <0.001, <0.001, <0.001, = 0.027, = 0.031, and <0.001 respectively), whereas the inplacebo group MCR (mean circular resultant) and PAIN deteriorated ( <0.001, <0.001). The changes in MNSIQ, QL, SNCV, BIO, and PAIN differed significantly between groups ( <0.001, <0.001, = 0.031, <0.001, and <0.001 respectively).

Conclusions: The combination of the four elements in one tablet for 12 months in patients with DMT2 improved all indices of peripheral neuropathy, including SNAP and SNCV, pain, and Quality of Life perception, except CARTs and MNSIE.

Citing Articles

Effect of high-dose N-acetyl cysteine on the clinical outcome of patients with diabetic peripheral neuropathy: a randomized controlled study.

Emara S, Fahmy S, AbdelSalam M, Wakeel L Diabetol Metab Syndr. 2025; 17(1):79.

PMID: 40038825 PMC: 11881454. DOI: 10.1186/s13098-025-01624-9.

Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy.

Didangelos T, Karlafti E, Kotzakioulafi E, Giannoulaki P, Kontoninas Z, Kontana A Nutrients. 2024; 16(18).

PMID: 39339645 PMC: 11434759. DOI: 10.3390/nu16183045.

Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach.

Atmaca A, Ketenci A, Sahin I, Sengun I, Oner R, Erdem Tilki H Front Endocrinol (Lausanne). 2024; 15:1380929.

PMID: 38952393 PMC: 11215140. DOI: 10.3389/fendo.2024.1380929.

Development and validation of a risk nomogram model for predicting peripheral neuropathy in patients with type 2 diabetes mellitus.

Luo L, Long X, Cheng C, Xu Q, Li J Front Endocrinol (Lausanne). 2024; 15:1338167.

PMID: 38742191 PMC: 11089122. DOI: 10.3389/fendo.2024.1338167.

Genetic and Transcriptomic Background of Oxidative Stress and Antioxidative Therapies in Late Complications of Type 2 Diabetes Mellitus: A Systematic Review.

Tonin G, Dolzan V, Klen J Antioxidants (Basel). 2024; 13(3).

PMID: 38539811 PMC: 10967328. DOI: 10.3390/antiox13030277.

References

Azmi S, Jeziorska M, Ferdousi M, Petropoulos I, Ponirakis G, Marshall A . Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia. 2019; 62(8):1478-1487. PMC: 6647173. DOI: 10.1007/s00125-019-4897-y. View

Javed S, Petropoulos I, Alam U, Malik R . Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015; 6(1):15-28. PMC: 4269610. DOI: 10.1177/2040622314552071. View

Leishear K, Boudreau R, Studenski S, Ferrucci L, Rosano C, de Rekeneire N . Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. J Am Geriatr Soc. 2012; 60(6):1057-63. PMC: 3376015. DOI: 10.1111/j.1532-5415.2012.03998.x. View

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

Garcia-Alcala H, Santos Vichido C, Islas Macedo S, Genestier-Tamborero C, Minutti-Palacios M, Hirales Tamez O . Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. J Diabetes Res. 2015; 2015:189857. PMC: 4539458. DOI: 10.1155/2015/189857. View

Waldfogel J, Nesbit S, Dy S, Sharma R, Zhang A, Wilson L . Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017; 88(20):1958-1967. DOI: 10.1212/WNL.0000000000003882. View

Romao S . Therapeutic value of oral supplementation with melon superoxide dismutase and wheat gliadin combination. Nutrition. 2015; 31(3):430-6. DOI: 10.1016/j.nut.2014.10.006. View

Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R . Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27(7):639-53. DOI: 10.1002/dmrr.1239. View

de Jager J, Kooy A, Lehert P, Wulffele M, van der Kolk J, Bets D . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340:c2181. PMC: 2874129. DOI: 10.1136/bmj.c2181. View

10.

Clemente M, De Virgiliis S, Kang J, Macatagney R, Musu M, Di Pierro M . Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003; 52(2):218-23. PMC: 1774976. DOI: 10.1136/gut.52.2.218. View

11.

Ishibashi F, Taniguchi M, Kosaka A, Uetake H, Tavakoli M . Improvement in Neuropathy Outcomes With Normalizing HbA in Patients With Type 2 Diabetes. Diabetes Care. 2018; 42(1):110-118. DOI: 10.2337/dc18-1560. View

12.

Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S . One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. Diabet Med. 2018; 35(7):887-894. PMC: 6033008. DOI: 10.1111/dme.13630. View

13.

Sandkuhler J . Models and mechanisms of hyperalgesia and allodynia. Physiol Rev. 2009; 89(2):707-58. DOI: 10.1152/physrev.00025.2008. View

14.

Ponirakis G, Abdul-Ghani M, Jayyousi A, Almuhannadi H, Petropoulos I, Khan A . Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7312325. DOI: 10.1136/bmjdrc-2020-001420. View

15.

Latremoliere A, Woolf C . Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(9):895-926. PMC: 2750819. DOI: 10.1016/j.jpain.2009.06.012. View

16.

Moura F, de Andrade K, Dos Santos J, Goulart M . Lipoic Acid: its antioxidant and anti-inflammatory role and clinical applications. Curr Top Med Chem. 2015; 15(5):458-83. DOI: 10.2174/1568026615666150114161358. View

17.

. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1995; 122(8):561-8. DOI: 10.7326/0003-4819-122-8-199504150-00001. View

18.

Giorgino F, Home P, Tuomilehto J . Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. Diabetes Care. 2016; 39 Suppl 2:S187-95. DOI: 10.2337/dcS15-3023. View

19.

Cakici N, Fakkel T, van Neck J, Verhagen A, Coert J . Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016; 33(11):1466-1476. DOI: 10.1111/dme.13083. View

20.

Kalso E, Aldington D, Moore R . Drugs for neuropathic pain. BMJ. 2013; 347:f7339. DOI: 10.1136/bmj.f7339. View